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CObjectives: In low- and middle-income countries, patients and reim-
bursement agencies that purchase medicines in the private sector pay
more for originator brands when generic equivalents exist. We esti-
mated the savings that could be obtained from a hypothetical switch in
medicine consumption fromoriginator brands to lowest-priced generic
equivalents for a selection of medicines in 17 countries. Methods: In
this cost minimization analysis, the prices of originator brands and
their lowest-priced generic equivalents were obtained from facility-
based surveys conducted by using a standard methodology. Fourteen
medicines most commonly included in the surveys, plus three statins,
were included in the analysis. For eachmedicine, the volume of private
sector consumption of the originator brand product was obtained from
IMS Health, Inc. Volumes were applied to the median unit prices for
both originator brands and their lowest-priced generics to estimate
cost savings. Prices were adjusted to 2008 by using consumer price
index data andwere adjusted for purchasing power parity.Results: For O
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ttp://dx.doi.org/10.1016/j.jval.2012.04.004he medicines studied, an average of 9% to 89% could be saved by an
ndividual country from a switch in private sector purchases from orig-
nator brands to lowest-priced generics. In public hospitals in China, US
370 million could be saved from switching only four medicines, sav-
ng an average of 65%. Across individual medicines, average potential
avings ranged from 11% for beclometasone inhaler to 73% for ceftri-
xone injection. Conclusions: Substantial savings could be achieved
y switching private sector purchases from originator brandmedicines
o lowest-priced generic equivalents. Strategies to promote generic up-
ake, such as generic substitution by pharmacists and increasing con-
dence in generics by professionals and the public, should be included
n national medicines policies.
eywords: affordability, cost, developing countries, generics, medi-
ines, originator brands, pharmaceuticals, savings.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
In low- and middle-income countries (LMICs), a significant propor-
tion of the population lack access to essential medicines [1]. While
many LMICs providemedicines for free or at low cost in public sector
facilities, availability isoften low [2]. Furthermore,while socialhealth
nsurance schemes are expanding in LMICs, overall coverage in low-
ncomecountries remainspoor [3] andmanyschemesdonotprovide
edicines benefits or do so with substantial co-payments [4,5]. As a
esult,medicines are still primarily purchased throughout-of-pocket
ayments in the private sector [6] where high prices can be a barrier
o access [2,6–11]. Given the important and often dominant role of
he private sector in supplying medicines in LMICs [12], national
edicines policies (NMPs) often include efforts to manage the per-
ormance of this sector so as to make medicines available at an af-
ordable cost [13,14]. The majority of LMICs have an NMP [14], a pri-
ary objective of which is securing the population’s access to
edicines necessary to achieve major public health goals [15].
The use of genericmedicines is often promoted as ameasure to
educe medicine costs and increase consumer access and can be
* Address correspondence to: Alexandra Cameron, UNITAID, 20 A
E-mail: camerona@unitaid.who.int.
† Alexandra Cameron was employed at Essential Medicines
witzerland at the time of authorship.
098-3015/$36.00 – see front matter Copyright © 2012, Internation
ublished by Elsevier Inc.ncluded in NMPs as part of strategies to encourage the cost-effec-
ive use of medicines by health professionals and consumers [16].
n LMICs, originator brand medicines that have come off patent
enerally cost substantially more than do their generic equiva-
ents. Patients purchasing medicines in the private sector pay, on
verage, 2.6 timesmore for originator brands than for their lowest-
riced generic equivalent [2]. In some countries, this price differ-
ntial is more than 10-fold. When higher-cost originator brands
re the only products available at a given dispensing point, pa-
ients may be forced to forgo treatment or may be pushed into
overty as a result of medicine purchases. A study of the impov-
rishing effect of purchasing medicines in 16 LMICs found that an
dditional 10% to 17% of the population would be pushed under
he $1.25/d poverty line as a result of purchasing individual med-
cines as originator brands [17]. If the same medicines were pur-
hased as lowest-priced generic equivalents, the impoverishing
ffect was substantially lower (2%–7%). Themagnitude of price dif-
erential between brands can be influenced by the presence/absence
nd nature of price regulations and reimbursement policies; for ex-
mple, restricting reimbursement to the price of lower-cost products
e Appia, CH-1211, Geneva 27, Switzerland.
Pharmaceutical Policies, World Health Organization, Geneva,
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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665V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 6 6 4 – 6 7 3was found to reduce and stabilize retail prices in Kyrgyzstan [18]. In
nregulated markets, price differentials will be influenced by pa-
ients’ willingness to pay for higher-priced products [15].
The organization of a country’s health system can have impli-
ations for medicine prices and overall spending. In fully public
ystems, medicines are financed, procured, and distributed by a
entralized government unit at the national or state/provincial
evel; in mixed systems, public funding from central budgets or
ocial health insurance is used to reimburse patients or private
harmacies, or medicines are supplied through governmentmed-
cal stores and health facilities but paid for by patient fees; in fully
rivate systems, patients or private insurance systems pay the
ntire cost of medicines purchased from private pharmacies and
rug sellers.Most countries utilize a combination of two ormore of
hese approaches [13]. The organization of the pharmaceutical
ector, including the presence/absence of price regulations, will
nfluence overall spending, which is a function of both price levels
nd consumption volumes. AmongOrganization for Economic Co-
peration and Development countries, for example, Switzerland
nd Denmark have among the highest price levels but the lowest
er-capita spending, while France and Spain have among the low-
st prices but the highest per-capita spending due to high con-
umption volumes [19].
Market factors will also have an impact on pharmaceutical
rice levels. Pharmaceuticalmarkets are subject to several failures
hat prevent the production of socially optimal amounts of medi-
ines over time. A main source of failure is the information asym-
etry that exists between prescribers, dispensers, and consumers
egarding the quality, safety, efficacy, and value for money of in-
ividual medicines, which allows prescribers/dispensers to give
isleading advice to increase profits [13,20]. Market failures may
lso occur because of lack of competition, for example, monopoly
ower due to patent protection or barriers to market entry of ge-
eric competitors, leading to higher prices thanwould be expected
n a competitivemarket [13,20]. A further failure occurs because of
he externality of certain medicines used to treat communicable
iseases, where the benefits of treatment extend beyond the indi-
idual consuming the medicine. In a free market, the consump-
ion of these products will be less than optimal from a societal
erspective [13]. In countries where medicines are covered under
ealth insurance benefits, market failure may also occur because
f moral hazard. That is, consumers are inclined to overconsume
ecause they do not directly bear the cost of consumption [20].
nother potential source ofmarket failure is the underinvestment
or particular diseases [20]. As a result of these failures, pharma-
eutical markets are usually extensively regulated, far more so
han the markets for most other goods [13]. Government regula-
ions are often related to patents, marketing authorization, and
ricing and reimbursement [20]. Additional measures include in-
ormation and training for health professionals and consumers,
egulation of promotional practices to prevent the provision of
iased or inaccurate information, substitution of brand products
ith generic equivalents by dispensers, and subsidization of prod-
cts with externalities [13]. The nature of government interven-
ions in pharmaceuticalmarkets vary substantially between coun-
ries; for example, EU member states use a range of approaches
hat address both supply-side and demand-side issues [20].
In discussing the possible overreliance on higher-priced origi-
ator brands once patents have expired and generic competitors
ave entered the market, the market failure of primary concern is
hat caused by information asymmetry. Because of a limited un-
erstanding of the characteristics of individual products, consum-
rs often purchase a different medicine than they would if they
ere better informed [21]. To compensate for this lack of informa-
ion, consumers frequently rely on prescribers and/or dispensers
or advice on what to buy (“agency relationship”). Prescribers
nd/or dispensers, however, often advise on the basis of theirwn incentives rather than the buyer’s interests. For example,
hen wholesaler/retailer margins are a fixed percentage of the
rice, there is the incentive to stock and sell more expensive
roducts to obtain a greater profit [15]. Physicians’ prescribing
ehavior can also be influenced by pharmaceutical companies
hrough a variety of measures ranging from high-end education
rograms to cash payment for prescriptions [15]. As a result of
hese incentives, patients are often encouraged to use higher-
riced originator-branded products instead of equally effective,
ower-cost generics [21].
There is a wide variability in the uptake of generic medicines
cross high-income countries. For example, in Japan, generic
edicines represent only 16% of the prescription medicines mar-
et by volume, compared with 60% to 70% in the United Kingdom,
anada, and Germany [22]. Efforts have beenmade to increase the
ptake of generics in developing countries, and in some cases, to
uantify the cost savings achieved from these efforts. For exam-
le, the cost savings to UK’s National Health Service of a campaign
o promote themost cost-effective use ofmedicines through strat-
gies such as generic substitution have been estimated at £1 bil-
ion a year [23]. A review of European pricing and reimbursement
ystems reported on the budgetary impact of generic substitution
allowing/requiring pharmacists to dispense a generic equivalent
n place of the prescribed originator brand) in Finland based on
valuations conducted by the Finnish Social Insurance Institution
24]. Savings were estimated at €25.7 million in 2005, correspond-
ng to an average saving of €15.80 per substitution.Whenmedicine
rice reductions brought on by price competition were also in-
luded, the total cost savings were estimated at €88.3 million. An-
ther analysis found that in the 3 years following the introduction
f generic substitution at patent expiry in Sweden, the accumu-
ated savings in the pharmaceutical budget were about €760 mil-
ion [25]. Overall pharmaceutical prices decreased by 15%,with the
ighest decrease observed for statins (71%).
While results from high-income countries indicate that the
ost savings of increased use of genericmedicines can be substan-
ial, little is known about the economic impact of increased ge-
eric uptake in LMICs. This study estimates the potential savings
hat could be obtained by switching purchases from originator
rand medicines to the lowest-priced generic equivalents for a
election of multisource products (i.e., medicines produced by
ore than one manufacturer, including both the originator brand
nd generic equivalents) in developing countries. This informa-
ion is important for governments in considering which policy
nterventions could be undertaken to achieve the goals of an NMP.
ecause such policies have many possible components and re-
ources for implementation are limited, it is important to under-
tand where possible investments have the potential to achieve
he goal of improved access to quality medicines.
Methods
To estimate the maximum cost savings that could be generated if
the originator brand products consumed were purchased as low-
est-priced generics, final (retail) prices of both originator brands
and their lowest-priced generic equivalents were applied to the
volume of originator brand product consumed. Medicine price
data were obtained from surveys conducted by using a validated
[26] methodology developed by the World Health Organization
(WHO) and Health Action International (HAI) [27], while medicine
consumption datawere obtained from IMSHealth, Inc., a pharma-
ceutical market intelligence company (www.imshealth.com/). In
the WHO/HAI surveys, the median unit prices (e.g., price per tab-
let, mililiter) of approximately 50 medicines are calculated from
data collected in a sample of public and private sector facilities.
For eachmedicine, data are collected on both the originator brand
first authorized worldwide for marketing (normally as a patented
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666 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 6 6 4 – 6 7 3product) on the basis of the documentation of its efficacy, safety,
and quality, according to requirements at the time of authori-
zation, and the lowest-priced generic equivalent found at each
facility. In WHO/HAI surveys, generic medicines are defined as
pharmaceutical products intended to be interchangeable with
the originator brand product, manufactured without a license
from the originator manufacturer, and marketed after the ex-
piry of patent or other exclusivity rights [27]. Only registered
products distributed through regulated channels (e.g., licensed
pharmacies) are included, thereby reducing the risk that the
generics surveyed are of substandard quality or counterfeit.
Data are collected on the same medicine formulation (e.g., cap-
sule [cap]/tablet [tab] and slow release tablet) and strength for
originator brands and their generic equivalents, because such
treatment costs are directly comparable.
The survey method does not collect price data on medicines
provided free of charge or for a fixed fee. Discounted prices that
are offered to all patients are recorded. TheWHO/HAI method is
standardized across surveys through the use of a common sur-
vey manual and tools such as training resources. The survey
manual has been translated into five languages and provides
guidance on methodological adaptations to account for contex-
tual issues (e.g., geography). WHO/HAI survey data have been
used to generate national-level reports [28], to conduct second-
ary analyses [2,9,17,29], and as an information source for inter-
ational monitoring activities [30,31]. IMS collects pharmaceu-
ical consumption data from wholesalers, hospitals, and/or
ispensing outlets such as pharmacies or drugstores [32]. The
ethodology employed varies by country and is dependent on
he nature of each health system.
The 40 countries for which WHO/HAI pricing data were avail-
ble were compared with countries for which IMS Health con-
umption data were also available. A set of 17 developing coun-
ries, as designated by the United Nations system [33], was
dentified forwhich both data setswould be available to enable the
nalysis. Ukraine was also included even though it is not catego-
ized by the United Nations system as either a developed or devel-
ping country because it is a country of the Commonwealth of
ndependent States in Europe. In each of the 17 countries, price
ata are based on a national survey, with the exceptions of China
nd South Africa, where surveys were conducted on a subnational
evel. While data from South Africa represent a single province
Gauteng), in China results from two surveys (Shandong and
hanghai) were averaged without weighting as has been done in
revious studies [2]. Weighting by population size was considered
s a potential method to account for price variations that might
ccur as a result of differences in consumption volumes. However,
s a previous study showed only a very limited relationship be-
weenmedicine price and volumepurchases [34], the decisionwas
ade to use an unweighted average. All surveys were conducted
t a single point in time, with survey dates ranging from 2004 to
008. Next, the medicines included in the price and availability
urveys in these 17 countries were compared to identify the 15
ost commonly surveyed medicines for inclusion in the analysis.
his method, which has been previously applied [2], was used to
ncrease the comparability of study medicines across the coun-
ries. In addition to the 15 most frequently surveyed medicines, 3
tatins were also included in the analysis given the high price
ifferential between originator brands and generics for thesemed-
cines and the large volumes consumed.
For each study medicine, the originator brands included in
achprice and availability surveywas cross-checked against those
ollected through IMSHealth to ensurematched data on price and
olume for the same product. The volume of originator brand
edicines supplied through the retail sector in each country in
009 was then extracted in IMS standard units. Exceptions are
hina, where data were available from public hospitals only, andalaysia, where datawere available only for the combined private
ospital and retail sectors. For one of the selected medicines (hy-
rochlorothiazide 25 mg cap/tab), no consumption of the origina-
or brand product was reported by IMS Health in any of the study
ountries; it was therefore excluded from the analysis. The total
olumes for eachmedicine (specific dosage form and strength cor-
esponding to price data) as well as for the therapeutic class (IMS
natomical Therapeutic Chemical classification level 3) repre-
ented by each medicine were also obtained to estimate the con-
umption of each medicine as a proportion of total consumption
or its therapeutic class, as well as the consumption of the origi-
ator brand product as a proportion of total medicine consump-
ion (all products, i.e., brands and generics) for that molecule.
The private sector median unit prices of each medicine, for
oth originator brand and lowest-priced generic products, were
pplied to the volume of originator brand product consumed in
009 to estimate the cost savings that could be generated if all the
riginator brand products consumed were purchased as lowest-
riced generics. For China, where consumption data were avail-
ble only for public hospitals, public sector prices were used.
rices were adjusted to 2008 by using consumer price index data
or each country andwere converted from national currency units
o US dollars by using gross domestic product purchasing power
arities [35]. The year 2008 was used because this was the most
ecent year forwhich consumer price index and purchasing power
arity data were available at the time of analysis. Results for indi-
idual countries and individual medicines are reported as average
avings, total savings, and per-capita savings, with population for
he latter taken from a standard international source [36].
Results
Table 1 lists the 17 countries included in the analysis with key
indicators of pharmaceutical expenditures. In the majority of the
countries under study, private sector spending represents thema-
jority of total pharmaceutical expenditure. In countries such as
the Philippines, private sector spending is primarily out of pocket,
because the social health insurance system does not currently
include an outpatientmedicines benefit. In Thailand, Ukraine, and
Pakistan, the large majority of pharmaceutical spending comes
from the public sector.
The 17 medicines included in the analysis are listed in Table 2.
With the exception of the three statins, all study medicines were
included in at least 80% ofWHO/HAI surveys, therebymaximizing
the price data available for the analysis. Average medicine con-
sumption (all products, including originator brand and generics)
as a proportion of therapeutic class (Anatomical Therapeutic
Chemical classification level 3) ranged from more than 90% for
salbutamol 100 g/dose inhaler and co-trimoxazole 8 40 mg/mL
suspension to 7% for lovastatin 20 mg cap/tab. Across all individ-
ual medicines in all the countries studied, the average market
share (by volume) of the originator brand product was 39%, indi-
cating that for these multisource products the originator brands
still hold a substantial proportion of themarket. Large differences,
however, were observed across individual medicines, ranging
from 100% for amitryptilline 25 mg cap/tab to 3% for omeprazole
20mg cap/tab. For amitryptilline, it should be noted that originator
brand volumedatawere available only for four countries; the pres-
ence of WHO/HAI price data for generic amitryptilline in other
study countries confirms the presence of generic equivalents
though volumes are unknown.
The average, total, and per-capita potential cost savings that
could be obtained from switching consumption from originator
brands to lowest-priced generics are shown in Table 3 for the bas-
ket ofmedicines studied in each country.While 17medicineswere
included in the study, the absence of volume and/or price data for
individualmedicines limited the number ofmedicines analyzed in
Table 1 – Countries included in the analysis (both IMS-Health medicine consumption data and WHO/HAI medicine price data were available), with pharmaceutical
expenditure indicators.
Country (WHO/HAI
survey year)
Year of
pharmaceutical
expenditure data
Per-capita total
pharmaceutical
expenditure
(TPE) (constant
year, 2005), USD
PPP
TPE as %
of GDP
TPE as % of total
health
expenditure
Pharmaceutical private
spending as % of TPE
Per-capita public
pharmaceutical
spending
(constant year,
2005), USD PPP
Per-capita private
pharmaceutical
spending
(constant year,
2005), USD PPP
China* (2004, 2006) 2006 77.6 1.7 36.2 73.5 32.6 57.0
Colombia (2008) 2006 87.0 1.4 19.3 77.9 19.2 67.7
Ecuador (2008) 2006 128.9 1.9 35.1 77.6 28.8 100.0
Indonesia (2004) 2006 22.6 0.7 28.3 94.0 1.4 21.2
Jordan (2004) 2001 101.0 2.9 30.1 81.5 18.7 82.3
Kuwait (2004) 2006 126.0 0.3 13.6 ND 76.7 ND
Lebanon (2004) 1998 251.7 3.0 25.4 94.4 14.2 237.6
Malaysia (2004) 2005 71.3 0.6 14.7 66.0 24.2 47.0
Morocco (2004) 2006 54.6 1.4 27.1 ND ND ND
Pakistan (2004) 2001 18.1 1.0 43.7 41.5 10.6 7.5
Peru (2005) 2006 68.5 1.0 22.4 77.2 15.7 52.9
Philippines (2005) 2006 47.7 1.6 41.1 90.1 4.7 43.0
South Africa† (2004) 2006 100.5 1.2 14.5 ND ND ND
Thailand (2006) 2006 110.3 1.5 42.9 12.3 96.7 13.5
Tunisia (2004) 2006 229.9 3.5 67.6 ND 69.0 ND
Ukraine (2007) 2006 111.5 1.8 26.5 40.0 66.9 44.6
United Arab Emirates
(2006)
2006 208.8 0.4 15.4 — ND ND
Adapted from The World Medicines Situation 2011, 3rd ed., Lu Y, Hernandez P, Abegunde D, Edejer T. Geneva, Medicine Expenditures Annex, Switzerland: World Health Organization, 2011.
Available from: http://www.who.int/medicines/areas/policy/world_medicines_situation/en/index.html, with permission from the World Health Organization.
GDP, gross domestic product; HAI, Health Action International; ND, no data; PPP, purchasing power parity; USD, United States dollar; WHO, World Health Organization.
* Medicine price data based on two subnational surveys conducted in Shandong province (2004) and Shanghai (2006).
† Medicine price data based on a subnational survey conducted in Gauteng province.
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668 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 6 6 4 – 6 7 3each country, ranging from 12 medicines in Ecuador and the
United Arab Emirates to 3 medicines in Tunisia. Across the coun-
tries studied, an average of 60% could be saved from a switch in
private sector purchases from originator brands to lowest-priced
Table 2 – Medicines included in the analysis.
Medicine Medicine category % of W
surve
included
Aciclovir 200 mg cap/tab Antiviral
Amitryptilline 25 mg cap/tab Antidepressant
Atenolol 50 mg cap/tab Cardiovascular
Atorvastatin 10 mg cap/tab Cardiovascular
Beclometasone 50 g/dose
inhaler
Antiasthmatic
Captopril 25 mg cap/tab Cardiovascular 1
Carbamazepine 200 mg cap/tab Antiepileptic
Ceftriaxone 1 g/vial injection Antibacterial 1
Ciprofloxacin 500 mg cap/tab Antibacterial
Co-trimoxazole suspension
8  40 mg/mL
Antibacterial
Fluoxetine 20 mg cap/tab Antidepressant 1
Glibenclamide 5 mg cap/tab Antidiabetic 1
Lovastatin 20 mg cap/tab Cardiovascular
Omeprazole 20 mg cap/tab Antiulcerant 1
Ranitidine 150 mg cap/tab Antiulcerant 1
Salbutamol 100 g/dose inhaler Antiasthmatic 1
Simvastatin 20 mg cap/tab Cardiovascular
Average (Min, Max)
ATC, Anatomical Therapeutic Chemical; cap, capsule; HAI, Health A
World Health Organization.
Table 3 – Total potential cost savings and average percenta
sector consumption from originator brands to lowest-price
Country* (n  number of
medicines)
Average percentage sa
across individual med
(%) (95% CI) (min, m
China, public hospitals (n  4)‡ 65  26 (38, 93)
Colombia (n  9) 89  4 (76, 97)
Ecuador (n  12) 63  10 (40, 90)
Indonesia (n  9) 84  6 (65, 95)
Jordan (n  11) 56  8 (33, 78)
Kuwait (n  6) 9  8 (5, 25)
Lebanon (n  8) 68  9 (51, 85)
Malaysia, private hospital and
retail sectors (n  10)
67  8 (45, 85)
Morocco (n  6) 52  18 (18, 78)
Pakistan (n  9) 51  19 (0, 86)
Peru (n  11) 79  11 (33, 92)
Philippines (n  9) 57  9 (24, 69)
South-Africa (n  7)§ 79  12 (41, 93)
Thailand (n  7) 76  13 (44, 93)
Tunisia (n  3) 26  13 (14, 36)
Ukraine (n  5) 52  39 (10, 95)
United Arab Emirates (n  12) 53  6 (31, 74)
Average 60
CI, confidence interval; Int$, international dollars; max, maximum; m
* Results refer to the private sector unless otherwise indicated.
† Simple average of the percentage savings for individual medicines
‡ Price data are from the public sector and are based on two surveys
§ Price data based on a survey conducted in Gauteng province (2004).generic equivalents. Notably high cost savings of more than 80%
were obtained in Colombia and Indonesia, while more than three
quarters of current spending could be saved in Peru, South Africa,
and Thailand.While Pakistan and the Philippines had lower-than-
AI
at
icine
Mean % consumption as
proportion of
therapeutic class (ATC
level 3) (min, max)
Mean % consumption of
originator brand product
as a proportion of
medicine consumption
(min, max)
60.1 (16.1, 95.6) 28.8 (0.7, 100)
25.0 (0.2, 71.6) 100 (100, 100)
30.9 (1.7, 62.0) 36.3 (1.9, 93.0)
30.5 (8.2, 55.1) 60.6 (2.8, 100)
37.8 (0.0, 99.2) 39.3 (0.0, 95.7)
23.9 (0.0, 88.8) 31.9 (0.0, 100)
20.0 (0.0, 42.1) 62.3 (15.0, 100)
52.4 (2.0, 96.4) 20.1 (0.0, 74.0)
57.9 (1.6, 85.2) 11.1 (0.2, 25.0)
99.3 (93.4, 100) 24.4 (0.0, 77.4)
14.8 (5.6, 27.5) 27.3 (0.8, 90.8)
49.0 (4.6, 91.6) 34.6 (0.8, 93.3)
6.9 (0.0, 52.5) 65.5 (30.9, 100)
32.5 (9.2, 66.5) 3.4 (0.0, 20.8)
21.8 (6.4, 43.8) 25.5 (0.0, 93.2)
95.3 (56.8, 100) 71.0 (0.0, 100)
30.6 (2.1, 70.8) 12.6 (0.2, 57.9)
40.5 (6.9, 99.3) 38.5 (3.4, 100)
International; max, maximum; min, minimum; tab, tablet; WHO,
avings that could be obtained from switching private
nerics, by county.
s
s
Total potential cost
savings (2008 Int$)
Per-capita cost
savings (2008
Int$)
369,889,300 0.28
7,757,442 0.17
4,813,935 0.33
15,259,172 0.07
1,810,218 0.34
44,785 0.02
4,035,033 1.00
16,682,860 0.64
8,338,820 0.27
38,830,406 0.24
5,141,464 0.19
38,183,032 0.45
6,601,871 0.14
3,997,118 0.06
758,853 0.08
1,287,355 0.03
8,787,523 2.16
31,301,717 0.38
inimum.
ucted in Shanghai (2006) and Shandong (2004) provinces.HO/H
ys th
med
89
94
94
11
89
00
83
00
94
94
00
00
44
00
00
00
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669V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 6 6 4 – 6 7 3average percentage savings (51% and 57%, respectively), large con-
sumption volumes resulted in the high observed absolute savings
in private sector purchases (more than Int$ 38 million in both
countries). Similarly in public hospitals in China, high consump-
tion volumes resulted in potential savings of about Int$ 370million
from switching only four medicines, saving patients an average of
65%.While these results illustrate themagnitude of potential sav-
ings in high-volume markets, absolute savings across countries
cannot be compared because of differences in population size and
medicine usage patterns. Per-capita potential cost savings range
from less than Int$ 0.05 in Kuwait and the Ukraine to Int$ 2.16 in
the United Arab Emirates; however, it should be underscored that
in these results medicine consumption from the private sector
only is being applied to the total populationwho accessmedicines
from public, private, and often other sectors (e.g., nongovernment
organization hospitals and dispensing doctors). In China, if the
savings from four public hospitals, which represent a relatively
small proportion of overall consumption, are calculated on a per-
capita basis, savings of nearly 30 cents per person are still possible.
Table 4 shows the total potential cost savings and average per-
centage savings that could be obtained from switching consump-
tion from originator brands to lowest-priced generics, by individ-
ual medicine. Average percentage savings range from 11% for
beclometasone 50 g/dose inhaler to 73% for ceftriaxone 1 g/vial
injection. For the latter medicine, this percentage savings would
amount to Int$ 275 million across the six countries for which data
were available.
To illustrate the country-level savings that could be incurred
from switching from brands to generics for a single medicine, in-
dividual results for omeprazole 20 mg cap/tab, ciprofloxacin 500
mg cap/tab, and atenolol 50 mg cap/tab are shown for individual
countries in Table 5. With the exception of Kuwait, savings of at
least 50% could be obtained for all three medicines in every coun-
try for which data were available. Average cost savings ranged
from about Int$ 1.9 million for atenolol to Int$ 4.7 million for
omeprazole, with relatively similar average percentage savings for
the three medicines (65%–71%). For omeprazole, a savings of 80%
ormore could be obtained in half the countries through a switch in
private sector consumption from the originator brand to the low-
est-priced generic product. In Colombia and Peru, more than 90%
Table 4 – Total potential cost savings and average percenta
sector consumption from originator brand to lowest-priced
Medicine* (n  number of countries) Average perc
Aciclovir 200 mg cap/tab (n  11)
Atenolol 50 mg cap/tab (n  13)
Atorvastatin 10 mg cap/tab (n  2)
Beclometasone 50 g/dose inhaler (n  2)
Captopril 25 mg cap/tab (n  12)
Carbamazepine 200 mg cap/tab (n  10)
Ceftriaxone 1 g/vial injection (n  5)
Ciprofloxacin 500 mg cap/tab (n  9)
Co-trimoxazole suspension 8  40 mg/mL (n  10)
Fluoxetine 20 mg cap/tab (n  10)
Glibenclamide 5 mg cap/tab (n  11)
Lovastatin 20 mg cap/tab (n  1)
Omeprazole 20 mg cap/tab (n  12)
Ranitidine 150 mg cap/tab (n  15)
Salbutamol 100 g/dose (n  8)
Simvastatin 20 mg cap/tab (n  7)
cap, capsule; CI, confidence interval; Int$, international dollars; max
* Amitryptilline 25 mg cap/tab is not included because no country in
† Simple average of the percentage savings for individual countries.savings could be achieved for omeprazole though the absolutesavings in these two countries are relatively small (approximately
Int$ 582,000 and 89,000, respectively) due to low volumes con-
sumed. A much higher absolute saving is obtained in public hos-
pitals in China (Int$ 43.6 million) owing to both the large volumes
consumed and a substantial price differential between the origi-
nator brand and lowest-priced generic products.
Discussion
The above analysis shows that cost savings of more than 50%
could be generated in all but two of the countries studied if the
consumption of the studied medicines shifted from originator
brand products to the lowest-priced generic equivalents available
at medicine outlets in the private sector. Results varied substan-
tially across individual countries, ranging from average percent
savings of more than 80% in Colombia and Indonesia to only 9% in
Kuwait. Differences in the percent savings across countries can be
due to market factors (e.g., size of market and number of compet-
itors) and/or national policies, such as price regulations, that in-
fluence the prices of originator brands and generic equivalents.
The countries in this study vary in their degree of pharmaceutical
price regulation aswell as in theirmethods of application. In coun-
tries such as Indonesia, Malaysia, and Ukraine, medicine prices
are not subject to regulations [37–39], while in countries such as
Jordan, Lebanon, andMorocco, prices are regulated using a variety
of methods [40–42]. In South Africa, price controls are applied to
medicine at various stages in the supply chain [43], while in Paki-
stan only selections of medicines are subject to price controls [44].
In Kuwait, the results of the WHO/HAI survey show that the low
price differential between originator brands and their generic
equivalents observed in this country is the result of high-priced
generics and not low-priced originator brands [45]. Across the 29
medicines surveyed in Kuwait, generics and originator brands
were priced at 15.7 and 17.5 times international reference prices,
respectively. In Kuwait, the retail prices ofmedicines in the private
sector are set by the government. The small price difference be-
tween originator brand and generic medicines is probably an in-
dication of generic medicines having their selling price based on
the selling price of the brand medicine rather than on the actual
avings that could be obtained from switching private
eric, by medicine.
ge savings across countries
CI) (min, max)†
Total potential cost savings
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670 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 6 6 4 – 6 7 3having an unintended effect of keeping generic prices higher than
what would be achieved through market competition and should
be revisited. Unfortunately, evidence is lacking on the presence or
absence of price regulations on pharmaceutical price levels and on
the impact of different types of price regulations. It should be
noted that to improve the comparability of results across coun-
tries, total cost savings have been adjusted for purchasing power
parity, which changed the results substantially formost countries.
Unadjusted cost savings, while not comparable across countries,
would better reflect national-level savings and are available as
Supplementary Materials at http://dx.doi.org/10.1016/j.jval.2012.
4.004.
Cost savings also varied across individual medicines, though
ost medicines had an average percent savings in the range of
0% to 70%. Reasons for variations across individual medicines
ould include time since patent expiry, with greater competition
ccurring in products that have been off patent for a longer period
f time. Indeed, omeprazole and ciprofloxacin, which have been
ff patent for a shorter period than other study medicines (10
ears), had among the highest potential cost savings (71% and
0%, respectively). Given that all the study medicines have been
ff patent for several years and that multiple generic equivalents
xist on the international market for each, the impact of time
ince patent expiry on price levels has probably not been fully
aptured. Interestingly, the two products with the lowest savings
ere inhalers, namely, beclometasone (11% average savings) and
albutamol (38% average savings). The technology required to pro-
uce inhalers comparedwith that required to produce tabletsmay
e such that generics are priced at levels closer to those of origi-
ator brands.
The results of this study are illustrative only and are subject to
ertain limitations. First, the choice of countries included in the
Table 5 – Potential cost savings and average percentage sa
consumption from originator brands to lowest-priced gene
Country* Omeprazole 20 mg cap/tab
Potential cost
savings (2008 Int$)
Percentage
savings (%) sa
China, public hospitals† 43,621,073 81
Colombia 582,296 97
Ecuador 6,240 84
Indonesia 2,659,927 82
Jordan 10,607 61
Kuwait 11,602 12
Lebanon ND ND
Malaysia, private hospital
and retail sectors
1,122,190 76
Morocco 1,929,864 78
Pakistan 4,672,532 80
Peru 88,576 92
Philippines 1,203,861 63
South Africa‡ ND ND
Thailand ND ND
Ukraine ND ND
United Arab Emirates 575,686 52
Total potential cost
savings
56,484,455
Average cost savings 4,707,038 71
cap, capsule; Int$, international dollars; ND, no data; tab, tablet.
* Results refer to the private sector unless otherwise indicated. Tun
these three medicines because of lack of data.
† Price data are from the public sector and are based on two surveys
‡ Price data based on a survey conducted in Gauteng province (2004)nalysis is dependent on the availability of both price data from wWHO/HAI surveys and volume data from IMS Health. They have
not been selected according to the level of generic penetration or
other characteristics. Second, the results of this analysis are
largely dependent on the selection of medicines used in the anal-
ysis. They have been selected on the basis of their frequency of
inclusion in WHO/HAI surveys to increase comparability across
countries. Thesemedicines, however,maynot reflect the products
with the highest national consumption overall, or those with the
largest consumption of brands in relation to generics. National
treatment practices as well as availability of alternative treat-
ments influence the volume share that each studymedicine holds
in its therapeutic class; however, volume shares of 20% ormore for
all but twomedicines show that the studymedicines are common
treatment choices. A further limitation is that for each medicine
included in the analysis, volume data as well as price data for both
the originator brand and the lowest-priced generic product were
needed to allow an estimation of cost savings. In no country stud-
iedwere all data available for all 17 targetmedicines, and in China,
Tunisia, and Ukraine fewer than 5 medicines had sufficient price
data to enable the cost savings estimate to be made. The general-
izability of the study results is also limited by the fact that medi-
cine prices collected between 2004 and 2008 were applied to con-
sumption data from 2009 and therefore do not take into account
price changes that could have occurred as a result of policy
changes, market fluctuations, or other factors. It should be noted,
however, that while individual surveys were conducted over a
4-year period, country-level prices of originator brands and gener-
ics were collected at the same time and are therefore comparable.
A further limitation lies in the fact that in China and South Africa,
price data were available only for a small number of provinces (2
and 1, respectively) and as such may not be representative of the
country as a whole. In a study conducted by Wang in 2006 [46], it
s that could be obtained from switching private sector
for three individual medicines.
floxacin 500 mg cap/tab Atenolol 50 mg cap/tab
ntial cost
s (2008 Int$)
Percentage
savings (%)
Potential cost
savings (2008 Int$)
Percentage
savings (%)
ND ND ND ND
ND ND 603,316 85
ND ND 441,646 50
ND ND 2,262,877 73
162,176 78 230,505 60
369 9 472 6
865,732 72 785,874 80
,454,603 85 1,509,044 72
ND ND ND ND
ND ND 14,240,335 62
ND ND 446,825 84
,707,674 65 1,426,862 69
,755,157 76 450,242 78
711,602 93 1,308,148 78
196,809 95 ND ND
,002,784 58 594,658 52
,856,907 24,300,804
,428,545 70 1,869,293 65
not included because cost savings estimates were not available for
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671V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 6 6 4 – 6 7 3procured by hospitals in Chinamay differ by hospital size, a factor
thatmay translate into differences in prices charged to patients. A
study of Hubei province, China, using similar methods found con-
sistent results in terms of a high price differential between origi-
nator brands and generics; however, it was also noted that brands
were not widely available in this rural province where patients
cannot afford them [47].
Despite these limitations, this study demonstrates the poten-
ial for improving the cost-effective use of medicines through
reater use of quality assured lower-cost generics. Evenwhen they
re not the principal payer, governments may consider interven-
ng in this area to improve access to affordable medicines and
ealize the policy objectives laid out in their NMP. Government
ntervention should be aimed at supporting buyers who would
ake different purchase decisions if equipped with information
bout the range of products available. In the context of private
ector pharmaceutical markets in LMICs, this represents the ma-
ority of purchasers and an even greater proportion of the low-
ncome population who are less likely to have information and
ore likely to be pushed into financial hardship as a result of
edicine purchases [48]. It should be recognized, however, that
here is also a segment of the population who are informed of the
reatment options available and are willing to pay higher prices to
urchase brands.
In implementing NMPs, governments in LMICs have a range of
ossible interventions to choose from, targeting issues of quality
nd safety, selection, procurement, supply and distribution, and
se. The information provided in this article suggests that in
MICs, promoting the use of generic medicines for off-patent
roducts may be an important strategy for improving access to
edicines for the poor. Countering the information asymmetries
hat act as a barrier to the use of generic medicines requires both
nterventions to ensure that 1) patients and consumers are in-
ormed of the existence of these products and 2) prescribers and
ispensers have incentives (or at least do not have disincentives)
o supply these products. Possible interventions include the fol-
owing:
Increasing confidence in generics and promoting their accep-
tance by professionals, patients, and the general community;
Encouraging/requiring prescribers to prescribe generic medi-
cines;
Generic substitution by pharmacists;
Incentives for wholesalers and retailers to supply genericmed-
icines, for example, regressive mark-up schemes that allow
greater margins for lower-priced products; and
Selective financing of generic medicines, for example, by reim-
bursing all equivalent/similar medicines at the same price
[27,49].
multipronged strategy that employs a range of interventions is
ikely to be more successful, recognizing that an essential precon-
ition to any strategy promoting generic uptake is awell-function-
ng regulatory system that can ensure that medicines are of as-
ured quality. In Australia, a reimbursement policy by which
atients were reimbursed only at the cost of the lowest-priced
enerics found that after 4 years these products represented only
7% of prescriptions dispensed. When generic substitution was
dded, themarket share of these products increased to 54% [50]. In
ost developed countries, policies and strategies that address
rescribing and dispensing practices are used alongside those that
ddress supply-side issues, such as market entry and penetration
f generics, and pricing and reimbursement policies [49]. Exam-
les of the use of these policy tools in developing countries are
imited. AWHO survey in 2007 found that generic substitutionwas
ermitted in 75% of LMICs [14]. Incentives for private pharmacies
o dispense generics was practiced in 30% and 27% of low- andmiddle-income countries, respectively, and the prescription of ge-
neric medicines in the private sector was mandatory in 22% and
28% of low- and middle-income countries, respectively. There are
also examples of regressive mark-up schemes from countries
such as Iran, Lebanon, Syria, South Africa, and Tunisia [51]. While
the existence of such policies is a positive step toward promoting
generic medicine use, effective implementation is likely to be
challenging in resource-constrained settings. While there may
also be a role for generic manufacturers in promoting the use of
their products, objective information from a neutral third-party is
needed to address the information asymmetries that characterize
pharmaceutical markets and prevent consumers frommaking in-
formed choices.
Substandard and counterfeit medicines are a valid concern,
particularly in countries that lack a stringent regulatory authority,
and can undermine prescribers’ and patients’ confidence in gener-
ics as a whole. However, prescribers and dispensers who benefit
from the sale of higher-cost medicines (e.g., whenmargins are set
as a percentage of the price) may also encourage the perception
that generics are less effective and/or unsafe and that originator
brand products are superior [15]. When medicines provided
through official channels are highly priced, it pushes patients to
purchase medicines in unregulated sectors (e.g., street markets)
where substandard and counterfeit medicines are most often
found [52]. It is therefore particularly important that low-cost,
quality-assured generics be made available through regulated
channels (both public and private). If a generic product has been
shown to be therapeutically equivalent, for example, through in
vivo bioequivalence testing or othermethods, it can be considered
interchangeable with the originator brand product in terms of
safety and efficacy [53], though other product characteristics, such
as taste, smell, or packaging, may differ. The issue of interchange-
ability of brands and generics is the subject of debate in certain dis-
ease areas (e.g., epilepsy) where some treatments have a narrow
therapeutic index, and therefore a higher risk of loss of efficacy
and/or toxicity [54,55]. Stringent regulatory control including the ca-
pacity to ensure quality is particularly important in these cases to
allow the most cost-effective medicines to be used while ensuring
patient safety. The issue of changing patients’ treatment to take ad-
vantage of lower prices and its impact on adherence could also be a
concern. While data are limited, one study of hypertensive patients
in the Netherlands showed that generic substitution of antihyper-
tensive drugs did not lead to lower adherence,more discontinuation
of treatment, or higher cardiovascular disease–related hospitaliza-
tions compared with brand-name therapy [56].
It should be emphasized that the generic medicines used in
this study represent the lowest-priced products registered in the
country and available in regulated facilities at the time of the sur-
vey. Lower-priced products are often available through unregu-
lated channels (e.g., street vendors); however, because the quality
of these products cannot be assured, they did not factor into this
analysis. Conversely, the use of higher priced generic equivalents,
such as branded generics, would not produce as high a saving. In
addition, the estimates in the study reflect a total shift in con-
sumption from originator brand products to their generic equiva-
lents, which does not represent a feasible scenario under real-
world conditions. A study that investigated the impact of generic
substitution in Sweden in the first year of implementation found
that the actual savings achieved were on average 60% of the total
possible savings and largely depended on the extent to which
pharmacies kept the cheapest brand in stock [57]. However, coun-
tries such as Denmark, Czech Republic, Turkey, and Poland have
achieved generic medicine consumption of more than 50% of the
total pharmaceuticalmarket by volume [58], and themarket share
of generic medicines has risen over each of the past 5 years in the
United States and now accounts for 78% of all prescriptions dis-
pensed [59]. Opportunities may therefore exist for LMICs to im-
t
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672 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 6 6 4 – 6 7 3prove generic uptake and by consequence, improve the affordabil-
ity of treatment for their populations.
The data presented in this article reflect a static analysis of
prices and consumption volumes, which themselves are not static
and will vary over time. Policies to change consumption toward
lower-price generics may affect price levels as well as total con-
sumption volumes. For example, the increased use of lowest-
priced generics could induce originator brand manufacturers to
reduce their prices, thereby reducing cost savings. One study of
generic substitution in Finland found that a substantial amount of
cost savings was attributable to price competition generated by
substitution, as opposed to substitution itself [60]. The potential
impact of the increased use of lowest-priced generics on con-
sumption is difficult to predict because of a lack of data on the
price elasticity of demand for medicines in LMICs. While price
elasticity of individual demandmay be lower for pharmaceuticals
than for other health services [61], and is generally low [15]. Given
hat lower-income consumers are generally more price sensitive
61], however, promoting the use of lower-priced generics may
esult in an increase in overall demand or a shift in demand from
he informal sector to the formal private sector.
Recognizing the dynamic nature of pharmaceutical markets,
his study serves to illustrate the potential to improve cost-effec-
ive medicine use through a shift in consumption from originator
rands to lowest-priced generics in a selection of developing coun-
ries. While such estimates have been previously conducted in
eveloped countries, to the authors’ knowledge it is the first time
hat such an analysis has been conducted in developing countries.
urther research into the determinants of the relative market
hares of originator brands and generics in developing countries,
he price elasticity of demand formedicines in these countries, the
ffects of pharmaceutical price regulations and strategies to pro-
ote generic medicine use, and the possible effects of shifts in
onsumption from originator brands to generics on price levels
ould help to refine the estimates of cost savings that could be
chieved.
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